SIM
VIRX

Spark Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Spark Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,271
Closed -$94K – 756
2018
Q2 		$94K Sell
1,271
-872
-41% -$77.6K 0.01% 604
2018
Q1 		$204K Buy
+2,143
New +$368K 0.01% 507

Other funds holding VIRX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Spark Investment Management's VIRX Position: Q3 2018 in Review

Spark Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2018, closing a stake of 1,271 shares — an estimated $94K sold.

Spark Investment Management first reported a position in VIRX in Q1 2018 and held it in 2 quarters. The position peaked at $204K in Q1 2018. 48 funds tracked by Wall St. Rank hold VIRX as of Q3 2018.

  • Spark Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Spark Investment Management sold 1,271 Viracta Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $94K.
  • Spark Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Spark Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $204K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Spark Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.